Remission induction in chronic granulocytic leukaemia using intermittent high-dose busulphan

In a series of 19 patients, the pre-blastic phase of chronic granulocytic leukaemia was controlled with busulphan given as single doses of 50-100 mg at 2-weekly intervals. Although there was no significant increase in the incidence of Ph1-negative cells in the bone marrow, remissions of a better haematological quality were attained more rapidly than with conventional therapy.